Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once‐Daily Oral Iron Chelator, With Midazolam, Rifampin, and Repaglinide in Healthy Volunteers

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of clinical pharmacology

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270009340418PMID 19940232
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Repaglinide

  2012cited by this paper
• Deferasirox

  2012influential reference
• Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam

  2009cited by this paper
• Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

  2008cited by this paper
• Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.

  2008cited by this paper
• Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects

  2008cited by this paper
• Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

  2008cited by this paper
• Concepts and goals in the management of transfusional iron overload

  2007cited by this paper
• Deferasirox : a review of its use in the management of transfusional chronic iron overload.

  2007cited by this paper
• Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide

  2006cited by this paper
• Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

  2006cited by this paper
• Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

  2006cited by this paper
• IN VITRO BLOOD DISTRIBUTION AND PLASMA PROTEIN BINDING OF THE IRON CHELATOR DEFERASIROX (ICL670) AND ITS IRON COMPLEX FE-[ICL670]2 FOR RAT, MARMOSET, RABBIT, MOUSE, DOG, AND HUMAN

  2006cited by this paper
• Evaluation of ICL670, a Once‐Daily Oral Iron Chelator in a Phase III Clinical Trial of β‐Thalassemia Patients with Transfusional Iron Overload

  2005cited by this paper
• No Clinically Relevant CYP3A Induction with the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240

  2004cited by this paper
• A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate

  2003cited by this paper
• Development of tridentate iron chelators: from desferrithiocin to ICL670.

  2003cited by this paper
• Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial.

  2003cited by this paper
• Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

  2001cited by this paper
• Simvastatin Does Not Affect CYP3A Activity, Quantified by the Erythromycin Breath Test and Oral Midazolam Pharmacokinetics, in Healthy Male Subjects

  2000cited by this paper
• Rifampin decreases the plasma concentrations and effects of repaglinide

  2000cited by this paper
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999cited by this paper
• Pharmacokinetic interaction between rifampin and zidovudine

  1993cited by this paper

• Ferroptosis and iron homeostasis in chronic obstructive pulmonary disease: Therapeutic opportunities of iron chelators.

  2025cites this paper
• CYP2C8-Mediated Drug–Drug Interactions and the Factors Influencing the Interaction Magnitude

  2025cites this paper
• Inhibition of repaglinide metabolism by letermovir prolonged severe hypoglycemia in a kidney transplant recipient: A case report and literature review

  2025cites this paper
• Quantitatively Predicting Effects of Exercise on Pharmacokinetics of Drugs Using a Physiologically Based Pharmacokinetic Model

  2024cites this paper
• Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications

  2024cites this paper
• A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6.

  2024cites this paper
• Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects.

  2022cites this paper
• Iron Overload

  2021cites this paper
• Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring

  2021cites this paper
• A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition

  2021cites this paper
• Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

  2020cites this paper
• Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models

  2020cites this paper
• Inhibition and induction of CYP enzymes in humans: an update

  2020cites this paper
• Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents

  2019cites this paper
• Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies.

  2019cites this paper
• Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter

  2018cites this paper
• Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects

  2017cites this paper
• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016cites this paper
• Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

  2016cites this paper
• Drug interactions in children with respiratory diseases in the pediatric unit of a teaching hospital in Brazil

  2016cites this paper
• Anesthetic Management of an Adolescent With Diamond-Blackfan Syndrome During Posterior Spinal Fusion

  2015cites this paper
• Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia

  2014influential citation
• Use of deferasirox in transfusion-dependent myelodysplastic syndromes with iron overload

  2014cites this paper
• For Review Only Effect of Phyllanthus amarus extract on the pharmacokinetics of midazolam in rabbits

  2014cites this paper
• Clinical Pharmacology of Deferasirox

  2014influential citation
• Update on rifampin, rifabutin, and rifapentine drug interactions

  2013cites this paper
• Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin

  2013influential citation
• Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin

  2013influential citation
• Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: Delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin

  2013influential citation
• Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

  2013cites this paper
• Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: Delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin

  2013influential citation
• Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia

  2013cites this paper
• Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.

  2012cites this paper
• Iron overload and toxicity: implications for anesthesiologists.

  2012cites this paper
• Severe hypoglycaemia from repaglinide–brotizolam drug interaction: a case report and literature review

  2012cites this paper
• Deferasirox: pharmacokinetics and clinical experience

  2012cites this paper
• The Pregnane X Receptor Agonist St John’s Wort Has No Effects on the Pharmacokinetics and Pharmacodynamics of Repaglinide

  2011cites this paper
• Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams

  2011cites this paper